{
    "data": [
        {
            "id": 2564305,
            "title": "Alnylam Pharma’s Strong Q3 Performance and Promising Outlook Reinforce Buy Rating Despite Legal Concerns",
            "description": "<p></p>\n<p>Joseph Stringer has given his Buy rating due to a combination of factors including Alnylam Pharma’s impressive financial performance and promising outlook. The company reported a significant increase in total product revenue for the third quarter of 2025, surpassing both the firm’s and market expectations. This growth was largely driven by the success of Amvuttra in treating ATTR-CM, which has led to an upward revision of the company’s revenue guidance for the year. <br> Despite some concerns over a subpoena from the U.S. Attorney’s Office, which may pose a short-term risk, the overall outlook for Alnylam’s TTR franchise remains positive. The strong revenue growth and the potential for continued success in their product launches have led to an increase in the price target, reinforcing the Buy rating. Stringer remains optimistic about the company’s future prospects, despite the current challenges.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2157214825-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/alnylam-pharmas-strong-q3-performance-and-promising-outlook-reinforce-buy-rating-despite-legal-concerns-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 04:05:34",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564307,
            "title": "Bandwidth’s Strong Q3 Performance and Strategic Growth Positioning Earns Buy Rating",
            "description": "<p></p>\n<p>Joshua Reilly has given his Buy rating due to a combination of factors that highlight Bandwidth’s strong performance and future potential. The company reported a robust third quarter, surpassing revenue and EBITDA expectations, which indicates solid financial health and operational efficiency. <br> Furthermore, Bandwidth is successfully onboarding large customers and securing significant deals, contributing to the acceleration of voice revenue. The integration of <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> and increased customer usage are expected to further enhance this growth trajectory. Additionally, the company’s platform, including Maestro, offers versatility to meet diverse customer needs, positioning Bandwidth well for future success. Reilly anticipates that the company’s progress towards its 2026 financial targets could lead to revenue outcomes that exceed current projections.</p>\n<p>Reilly covers the Technology sector, focusing on stocks such as Jamf Holding, Tyler Technologies, and HubSpot. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Reilly has an average return of <span style=\"color:green;font-weight:bold;\">0.5%</span> and a 39.85% success rate on recommended stocks. </p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2153315777-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/bandwidths-strong-q3-performance-and-strategic-growth-positioning-earns-buy-rating-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 04:05:43",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564289,
            "title": "Medicus Pharma Ltd’s Strategic Collaboration and Promising Phase 2 Results Justify Buy Rating",
            "description": "<p></p>\n<p>Jason McCarthy’s rating is based on Medicus Pharma Ltd’s strategic collaboration with the Gorlin Syndrome Alliance to advance their D-MNA patch for basal cell carcinoma (BCC). This partnership aims to facilitate an Expanded Access IND, allowing patients with Gorlin Syndrome to receive treatment while collecting real-world data, which could enhance the visibility and validation of their SkinJect technology.<br>Furthermore, the ongoing Phase 2 study has shown promising results with complete responses in BCC cases, and the collaboration could potentially attract support from Congressional caucuses focused on skin cancer and rare diseases. The potential for SkinJect to address a significant unmet need in treating BCC, coupled with positive feedback from the FDA, positions Medicus Pharma Ltd favorably in the market, justifying the Buy rating.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2051377127-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/medicus-pharma-ltds-strategic-collaboration-and-promising-phase-2-results-justify-buy-rating-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:55:13",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564277,
            "title": "Shake Shack Hold Rating: Balancing Brand Image and Rising Costs Amid Market Challenges",
            "description": "<p></p>\n<p>Andrew Charles has given his Hold rating due to a combination of factors affecting Shake Shack’s financial outlook. The company is facing industry challenges, particularly in balancing its premium brand image with the need to offer value in a slowing market. This is compounded by rising beef costs, which make up a significant portion of their cost of goods sold, necessitating price adjustments that could affect consumer perception.<br>Furthermore, while Shake Shack is making strides in marketing and menu innovation, these efforts have mixed results and place pressure on future earnings projections. The company’s recent sales strategies, including in-app discounts, have shown some promise in increasing traffic, but there is concern about the long-term impact on brand value and sales mix. Additionally, increased general and administrative expenses have led to a downward revision of adjusted EBITDA estimates for 2025 and 2026, further supporting the Hold recommendation.</p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Charles is a 4-star analyst with an average return of <span style=\"color:green;font-weight:bold;\">7.6%</span> and a 50.74% success rate. Charles covers the Consumer Cyclical sector, focusing on stocks such as McDonald’s, CAVA Group, Inc., and Starbucks.</p>\n<p>In another report released on October 23, UBS also maintained a Hold rating on the stock with a $104.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Cylical-6-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/shake-shack-hold-rating-balancing-brand-image-and-rising-costs-amid-market-challenges-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:45:21",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564222,
            "title": "Scotiabank Sticks to Their Buy Rating for TerraVest (TVK)",
            "description": "<p></p>\n<p></p>\n<p>In addition to Scotiabank, TerraVest also received a Buy from Canaccord Genuity’s Yuri Lynk in a report issued on October 23. However, yesterday, TR | OpenAI – 4o reiterated a Hold rating on TerraVest (TSX: TVK).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Energy-4-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/scotiabank-sticks-to-their-buy-rating-for-terravest-tvk-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:15:13",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564223,
            "title": "Dayforce Inc (DAY) Gets a Hold from TD Cowen",
            "description": "<p></p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Levine is an analyst with an average return of <span style=\"color:red;font-weight:bold;\">-6.0%</span> and a 33.33% success rate. Levine covers the Technology sector, focusing on stocks such as Paycom, Dayforce Inc, and Paylocity.</p>\n<p>In addition to TD Cowen, Dayforce Inc also received a Hold from Needham’s Scott Berg in a report issued today. However, on October 16, TR | OpenAI – 4o reiterated a Buy rating on Dayforce Inc (NYSE: DAY).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/12/shutterstock_2168929269.jpg",
            "link": "https://www.tipranks.com/news/blurbs/dayforce-inc-day-gets-a-hold-from-td-cowen-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:15:16",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564187,
            "title": "Capital Power (CPX) Gets a Buy from CIBC",
            "description": "<p></p>\n<p></p>\n<p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Capital Power with a C$76.38 average price target, which is a 7.70% upside from current levels. In a report released today, BMO Capital also maintained a Buy rating on the stock with a C$79.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1937012632-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/capital-power-cpx-gets-a-buy-from-cibc-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:05:45",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564188,
            "title": "National Bank Reaffirms Their Buy Rating on Capital Power (CPX)",
            "description": "<p></p>\n<p></p>\n<p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Capital Power with a C$76.38 average price target, representing a 7.70% upside. In a report released today, BMO Capital also maintained a Buy rating on the stock with a C$79.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1926207821-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/national-bank-reaffirms-their-buy-rating-on-capital-power-cpx-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:05:48",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564189,
            "title": "National Bank Remains a Buy on Maple Leaf Foods (MFI)",
            "description": "<p></p>\n<p></p>\n<p>Maple Leaf Foods has an analyst consensus of Strong Buy, with a price target consensus of C$34.80, a 26.68% upside from current levels. In a report released on October 22, TR | OpenAI – 4o also upgraded the stock to a Buy with a C$32.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Defensive-6-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/national-bank-remains-a-buy-on-maple-leaf-foods-mfi-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:05:51",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564190,
            "title": "Desjardins Reaffirms Their Buy Rating on Alaris Royalty (AD.UN)",
            "description": "<p></p>\n<p></p>\n<p>Currently, the analyst consensus on Alaris Royalty is a Moderate Buy with an average price target of C$23.33.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1020878011-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/desjardins-reaffirms-their-buy-rating-on-alaris-royalty-ad-un-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:05:54",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564191,
            "title": "CIBC Sticks to Its Buy Rating for Centerra Gold (CGAU)",
            "description": "<p></p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Bertozzi is a 2-star analyst with an average return of <span style=\"color:green;font-weight:bold;\">19.2%</span> and a 100.00% success rate. Bertozzi covers the Basic Materials sector, focusing on stocks such as NGEx Minerals, Centerra Gold, and Allied Gold Corporation.</p>\n<p>In addition to CIBC, Centerra Gold also received a Buy from Cormark Securities’s Richard Gray in a report issued today. However, on the same day, Raymond James maintained a Hold rating on Centerra Gold (NYSE: CGAU).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_519600637-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/cibc-sticks-to-its-buy-rating-for-centerra-gold-cgau-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:05:58",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564192,
            "title": "Acumen Capital Sticks to Their Buy Rating for Tamarack Valley Energy (TNEYF)",
            "description": "<p></p>\n<p></p>\n<p>In addition to Acumen Capital, Tamarack Valley Energy also received a Buy from CIBC’s Jamie Kubik in a report issued today. However, yesterday, Canaccord Genuity downgraded Tamarack Valley Energy (Other OTC: TNEYF) to a Hold.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Energy-9-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/acumen-capital-sticks-to-their-buy-rating-for-tamarack-valley-energy-tneyf-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:06:01",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564193,
            "title": "ATB Capital Markets Sticks to Its Buy Rating for Tamarack Valley Energy (TNEYF)",
            "description": "<p></p>\n<p></p>\n<p>In addition to ATB Capital Markets, Tamarack Valley Energy also received a Buy from CIBC’s Jamie Kubik in a report issued today. However, yesterday, Canaccord Genuity downgraded Tamarack Valley Energy (Other OTC: TNEYF) to a Hold.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Energy-5-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/atb-capital-markets-sticks-to-its-buy-rating-for-tamarack-valley-energy-tneyf-blurbs-2",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:06:04",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564194,
            "title": "J.P. Morgan Keeps Their Hold Rating on Bayer (0P6S)",
            "description": "<p></p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Vosser is a 3-star analyst with an average return of <span style=\"color:green;font-weight:bold;\">2.1%</span> and a 48.56% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novo Nordisk, and Sanofi.</p>\n<p>Bayer has an analyst consensus of Moderate Buy, with a price target consensus of €27.81, representing a 1.23% upside. In a report released on October 21, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a €27.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1061972606-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-hold-rating-on-bayer-0p6s-blurbs-2",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:06:09",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564181,
            "title": "Strong Financial Performance and Promising Pipeline Drive Buy Rating for Insmed",
            "description": "<p></p>\n<p>Ritu Baral’s rating is based on several positive developments for Insmed. The company’s recent financial performance has been strong, with Brinsupri’s third-quarter revenue significantly surpassing expectations. This success is attributed to a robust early launch in the non-cystic fibrosis bronchiectasis market, with a notable number of patients and prescribers engaged by the end of September.<br>Additionally, Insmed’s pipeline shows promise with upcoming trial data and new trials set to begin in the near future. The increase in the price target reflects the enhanced value from Brensocatib in chronic rhinosinusitis without nasal polyps. Furthermore, the company’s global revenue guidance for Arikayce has been raised, indicating continued growth and potential for further success. These factors collectively support the Buy rating given by Ritu Baral.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2068435553-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/strong-financial-performance-and-promising-pipeline-drive-buy-rating-for-insmed-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:05:21",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564183,
            "title": "Resilient Revenue and Strategic Positioning Support Buy Rating for Apellis Pharmaceuticals",
            "description": "<p></p>\n<p>Joseph Stringer has given his Buy rating due to a combination of factors influencing Apellis Pharmaceuticals. Despite some challenges, such as the ongoing co-pay issues affecting new patient starts and a slight decrease in market share for their product Syfovre, the company has shown resilience in its revenue performance. The revenue of $178 million was in line with market expectations, indicating stable demand.<br>Moreover, the management’s confidence in achieving sustainable profitability with their current cash reserves and product sales further supports the positive outlook. Although there are market headwinds, including a reduced revenue forecast for a competitor’s product, these factors are seen as manageable. Overall, the company’s strategic position and financial health contribute to the Buy rating.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1561815367-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/resilient-revenue-and-strategic-positioning-support-buy-rating-for-apellis-pharmaceuticals-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:05:30",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564186,
            "title": "Strong Buy Rating for CCC Intelligent Solutions Holdings: Robust Growth and Promising Future Prospects",
            "description": "<p></p>\n<p>Dylan Becker has given his Buy rating due to a combination of factors that highlight CCC Intelligent Solutions Holdings’ strong performance and promising future prospects. The company reported a robust third quarter with a 12% increase in revenue and a 41% EBITDA margin, surpassing market expectations. This growth is attributed to the company’s successful acquisition of large new clients, expansion with existing customers, and a return to normal claims volume trends.<br>Furthermore, CCC’s connected platform, which integrates AI-powered solutions, is experiencing significant demand across the automotive claims lifecycle. Notably, the company has secured key contracts with major carriers, including a new partnership with Liberty Mutual. These developments suggest a favorable business environment that is expected to sustain growth into the coming years. The company’s strategic positioning and potential for further organic growth, particularly with the integration of the EvolutionIQ business, support the expectation of consistent revenue growth and margin expansion.</p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Becker is a 4-star analyst with an average return of <span style=\"color:green;font-weight:bold;\">10.0%</span> and a 58.77% success rate. Becker covers the Technology sector, focusing on stocks such as Autodesk, Clearwater Analytics Holdings, and Guidewire.</p>\n<p>In another report released today, Barrington also maintained a Buy rating on the stock with a $14.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1437974372-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/strong-buy-rating-for-ccc-intelligent-solutions-holdings-robust-growth-and-promising-future-prospects-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 03:05:41",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564165,
            "title": "Thryv Holdings: Buy Rating Reaffirmed Despite SaaS Revenue Challenges",
            "description": "<p></p>\n<p>Scott Berg has given his Buy rating due to a combination of factors that highlight both challenges and opportunities for Thryv Holdings. Despite the company’s disappointing third-quarter financial results, with SaaS revenues falling short of expectations and adjusted EBITDA below guidance, Berg sees value in the current stock price. The shares have dropped significantly, over 25%, which Berg attributes to a revised outlook on SaaS revenue growth slowing down to single digits by fiscal year 2026 before stabilizing. <br> However, Berg maintains a positive outlook due to the company’s market segment (MS) revenues exceeding expectations, suggesting a net present value for this segment likely over $50 million. He believes the stock is undervalued, trading at approximately 0.5 times SaaS revenues, which he considers too low for a profitable SaaS segment that continues to grow. Therefore, he reiterates the Buy rating while adjusting the price target to $14 to account for the anticipated slower growth rate in SaaS revenues.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Communication-Services-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/thryv-holdings-buy-rating-reaffirmed-despite-saas-revenue-challenges-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:55:17",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564161,
            "title": "Federal Signal’s Strategic Growth and Strong Financial Performance Earns Buy Rating",
            "description": "<p></p>\n<p>Ross Sparenblek has given his Buy rating due to a combination of factors that highlight Federal Signal’s strong financial performance and strategic positioning. Despite a recent decline in share price, the company reported robust third-quarter results with a notable increase in order momentum. This performance led to an upward revision of the full-year revenue and adjusted EPS guidance, indicating confidence in future growth.<br>Furthermore, Federal Signal’s strategic moves, such as the anticipated acquisition of New Way, are expected to offset current order headwinds and enhance margins by capturing both OEM and dealer margins. The company’s operational strength is evident in its production volume growth and successful integration of Hog Technologies. Although lead times for certain products remain extended, this is seen as a sign of sustained municipal demand, providing visibility into 2026 and beyond, with continued organic growth potential through new product adoption.</p>\n<p>Sparenblek covers the Industrials sector, focusing on stocks such as Federal Signal, JBT Marel, and Kadant. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Sparenblek has an average return of <span style=\"color:green;font-weight:bold;\">11.3%</span> and a 60.98% success rate on recommended stocks. </p>\n<p>In another report released on October 15, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $131.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Industrials-9-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/federal-signals-strategic-growth-and-strong-financial-performance-earns-buy-rating-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:46:02",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564157,
            "title": "Phathom Pharmaceuticals: Strong Q3 Performance and Promising Growth Drive Buy Rating",
            "description": "<p></p>\n<p>Joseph Stringer has given his Buy rating due to a combination of factors including Phathom Pharmaceuticals’ strong financial performance in the third quarter of 2025. The company reported higher-than-expected revenue from its Voquezna product, surpassing both the firm’s estimates and the consensus forecast. Additionally, the company’s operating expenses were lower than anticipated, aligning with management’s goal of achieving profitability by 2026.<br>Furthermore, the positive quarterly results prompted Phathom to raise its lower-end revenue guidance for 2025 and reduce its non-GAAP operating expense forecast. The successful launch of Voquezna continues to show promising growth metrics, and management’s efforts to streamline expenses have been effective. Given these developments, Stringer believes the stock is currently undervalued and recommends buying on strength.</p>\n<p>Stringer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Moderna, and Avidity Biosciences. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Stringer has an average return of <span style=\"color:green;font-weight:bold;\">17.6%</span> and a 46.61% success rate on recommended stocks. </p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_390599908-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/phathom-pharmaceuticals-strong-q3-performance-and-promising-growth-drive-buy-rating-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:45:32",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564160,
            "title": "Bel Fuse Inc’s Strong Q3 Performance and Optimistic Outlook Lead to Buy Rating and Increased Target Price",
            "description": "<p></p>\n<p>James Ricchiuti has given his Buy rating due to a combination of factors including Bel Fuse Inc’s strong performance in the third quarter. The company demonstrated significant growth in its commercial sector, complemented by robust results in the aerospace and defense segments. This led to a revenue increase that surpassed market expectations, with sales rising 45% year-over-year compared to the anticipated 39%.<br>Furthermore, Bel Fuse Inc’s gross margins exceeded guidance, and operating expenses were lower than expected, resulting in earnings per share that were nearly 30% above what analysts had predicted. The positive momentum is expected to continue, as indicated by the company’s optimistic revenue guidance for the fourth quarter. Additionally, the successful integration of the Enercon acquisition has contributed to the company’s improved market position, prompting a target price increase from $130 to $168.</p>\n<p>Ricchiuti covers the Technology sector, focusing on stocks such as TTM Technologies, IMPINJ, and MKS. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Ricchiuti has an average return of <span style=\"color:green;font-weight:bold;\">14.4%</span> and a 56.97% success rate on recommended stocks. </p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1928816210-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/bel-fuse-incs-strong-q3-performance-and-optimistic-outlook-lead-to-buy-rating-and-increased-target-price-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:45:42",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564138,
            "title": "UTZ Brands (UTZ) Receives a Buy from Jefferies",
            "description": "<p></p>\n<p>Marks CFA covers the Consumer Defensive sector, focusing on stocks such as Saputo Inc., Sprouts Farmers, and Kraft Heinz. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Marks CFA has an average return of <span style=\"color:red;font-weight:bold;\">-2.3%</span> and a 52.17% success rate on recommended stocks. </p>\n<p>In addition to Jefferies, UTZ Brands also received a Buy from Barclays’s Andrew Lazar in a report issued today. However, on October 20, UBS maintained a Hold rating on UTZ Brands (NYSE: UTZ).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Defensive-2-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/utz-brands-utz-receives-a-buy-from-jefferies-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:35:22",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564139,
            "title": "Mizuho Securities Sticks to Its Buy Rating for Allegro MicroSystems (ALGM)",
            "description": "<p></p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Rakesh is a top 100 analyst with an average return of <span style=\"color:green;font-weight:bold;\">24.8%</span> and a 64.21% success rate. Rakesh covers the Technology sector, focusing on stocks such as Micron, Broadcom, and Nvidia.</p>\n<p>In addition to Mizuho Securities, Allegro MicroSystems also received a Buy from Needham’s Quinn Bolton in a report issued today. However, on October 16, TR | OpenAI – 4o reiterated a Hold rating on Allegro MicroSystems (NASDAQ: ALGM).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_264965759-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-allegro-microsystems-algm-blurbs-2",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:35:25",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564141,
            "title": "J.P. Morgan Reaffirms Their Buy Rating on Stellantis (STLA)",
            "description": "<p></p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Asumendi is a 4-star analyst with an average return of <span style=\"color:green;font-weight:bold;\">5.9%</span> and a 52.22% success rate. Asumendi covers the Consumer Cyclical sector, focusing on stocks such as Continental Aktiengesellschaft, Mercedes-Benz Group, and Bayerische Motoren Werke Aktiengesellschaft.</p>\n<p>Currently, the analyst consensus on Stellantis is a Hold with an average price target of $11.10, a 9.25% upside from current levels. In a report released today, Jefferies also maintained a Buy rating on the stock with a €11.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Cylical-9-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-buy-rating-on-stellantis-stla-blurbs-2",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:35:30",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564126,
            "title": "WEX Inc. Hold Rating: Balancing Financial Improvements with Competitive and Macroeconomic Challenges",
            "description": "<p></p>\n<p>Andrew Jeffrey has given his Hold rating due to a combination of factors, including WEX’s recent financial performance and market positioning. The company showed signs of improving financial consistency in the third quarter, with revenue and EBIT slightly surpassing expectations. This positive performance was primarily driven by the mobility segment, while corporate payments and benefits remained stable. Despite these improvements, Jeffrey expresses concerns about WEX’s competitive position in non-mobility segments, noting a lack of barriers that could hinder its growth compared to competitors like Corpay, which offers a more attractive risk/reward profile due to its diversified and faster-growing corporate payments.<br>Furthermore, while acknowledging WEX’s management for their solid execution and strategic focus, Jeffrey remains cautious about the company’s ability to achieve significant multiple expansion. The recent activism by Impactive Capital has contributed to share price appreciation, but the strategic portfolio review concluded that the current portfolio structure is optimal, potentially limiting the realization of a sum-of-the-parts valuation. Additionally, while the mobility segment showed growth, it still faces macroeconomic challenges, particularly in the trucking industry. These factors collectively support the Hold rating, indicating a balanced view of the company’s prospects.</p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Jeffrey is a 5-star analyst with an average return of <span style=\"color:green;font-weight:bold;\">13.5%</span> and a 62.20% success rate. Jeffrey covers the Technology sector, focusing on stocks such as Affirm Holdings, Fiserv, and Block.</p>\n<p>In another report released on October 28, Morgan Stanley also maintained a Hold rating on the stock with a $170.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1199235616-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/wex-inc-hold-rating-balancing-financial-improvements-with-competitive-and-macroeconomic-challenges-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:25:25",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564114,
            "title": "Agios Pharma’s Strong Commercial Execution and Clinical Progress Drive Buy Rating",
            "description": "<p></p>\n<p>Emily Bodnar has given her Buy rating due to a combination of factors, including Agios Pharma’s consistent commercial execution and progress towards key clinical milestones. The company reported steady commercial performance of Pyrukynd (mitapivat) in PKD, with a slight increase in net revenue, and is preparing for the PDUFA date for thalassemia in December 2025. Despite a delay due to FDA’s request for a REMS submission, the risk-benefit profile of Pyrukynd remains favorable, supporting its approval across all genotypes and levels of transfusion burden.<br>Additionally, Agios is making strong progress in its ex-US expansion, with a positive CHMP opinion in Europe and approval in Saudi Arabia, which mitigates the US extension delay. The upcoming RISE UP Phase 3 trial results for SCD, expected by the end of 2025, and the potential commercial launch in 2026 further bolster the company’s prospects. The Phase 2b tebapivat trial for LR-MDS is also on track, setting up another key data readout for early 2026. These developments, combined with favorable Phase 2 data for RISE UP, position Agios well for future growth.</p>\n<p>In another report released on October 17, Bank of America Securities also maintained a Buy rating on the stock with a $51.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2157214825-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/agios-pharmas-strong-commercial-execution-and-clinical-progress-drive-buy-rating-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:15:20",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564116,
            "title": "Promising 2026 Outlook for Tyler Technologies Amid Modest Q3 Performance",
            "description": "<p></p>\n<p>Joshua Reilly’s rating is based on Tyler Technologies’ Q3 performance aligning with expectations, showing a modest increase in revenue and earnings per share. Despite a year-over-year decline in SaaS annual recurring revenue due to significant deals from the previous year, the outlook for 2026 appears promising with anticipated 20% growth in SaaS revenue. <br> Reilly highlights that this growth is largely supported by business already secured, reducing concerns about potential slowdowns. Additionally, the possibility of large-scale deals returning in 2026, coupled with improving free cash flow margins, makes the current stock price attractive for investors.</p>\n<p>Reilly covers the Technology sector, focusing on stocks such as Jamf Holding, Tyler Technologies, and Karooooo. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Reilly has an average return of <span style=\"color:green;font-weight:bold;\">0.5%</span> and a 39.85% success rate on recommended stocks. </p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2170811717-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/promising-2026-outlook-for-tyler-technologies-amid-modest-q3-performance-ratings",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:15:29",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564117,
            "title": "Gildan Activewear (GIL) Receives a Buy from Canaccord Genuity",
            "description": "<p></p>\n<p></p>\n<p>In addition to Canaccord Genuity, Gildan Activewear also received a Buy from Barclays’s Paul Kearney in a report issued today. However, on October 20, Citi downgraded Gildan Activewear (NYSE: GIL) to a Hold.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Cylical-10-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/gildan-activewear-gil-receives-a-buy-from-canaccord-genuity-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:15:33",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564118,
            "title": "Kellanova (K) Gets a Hold from Jefferies",
            "description": "<p></p>\n<p>Marks CFA covers the Consumer Defensive sector, focusing on stocks such as Saputo Inc., Sprouts Farmers, and Kraft Heinz. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Marks CFA has an average return of <span style=\"color:red;font-weight:bold;\">-2.3%</span> and a 52.17% success rate on recommended stocks. </p>\n<p>Kellanova has an analyst consensus of Hold, with a price target consensus of $83.44.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Defensive-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/kellanova-k-gets-a-hold-from-jefferies-blurbs-2",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 02:15:37",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564035,
            "title": "Berenberg Bank Sticks to Their Buy Rating for Restore (RST)",
            "description": "<p></p>\n<p></p>\n<p>The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Restore with a p382.00 average price target, a 51.89% upside from current levels. In a report released on October 27, Canaccord Genuity also reiterated a Buy rating on the stock with a p404.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Industrials-5-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/berenberg-bank-sticks-to-their-buy-rating-for-restore-rst-blurbs-2",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:03",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564036,
            "title": "Glencore (GLEN) Gets a Hold from Berenberg Bank",
            "description": "<p></p>\n<p>Hatch covers the Basic Materials sector, focusing on stocks such as Glencore, Wheaton Precious Metals, and Anglo American. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Hatch has an average return of <span style=\"color:green;font-weight:bold;\">16.0%</span> and a 54.44% success rate on recommended stocks. </p>\n<p>In addition to Berenberg Bank, Glencore also received a Hold from J.P. Morgan’s Dominic OKane in a report issued on October 27. However, today, Morgan Stanley reiterated a Buy rating on Glencore (LSE: GLEN).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2135555081-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/glencore-glen-gets-a-hold-from-berenberg-bank-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:07",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564037,
            "title": "Essentra (ESNT) Gets a Buy from Berenberg Bank",
            "description": "<p></p>\n<p></p>\n<p>In addition to Berenberg Bank, Essentra also received a Buy from Jefferies’s Andrew Douglas in a report issued today. However, on October 25, TR | OpenAI – 4o reiterated a Hold rating on Essentra (LSE: ESNT).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2131048847-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/essentra-esnt-gets-a-buy-from-berenberg-bank-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:15",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564038,
            "title": "Stifel Nicolaus Keeps Their Buy Rating on Atome Energy PLC (ATOM)",
            "description": "<p></p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Round is ranked #9014 out of 10041 analysts.</p>\n<p>Currently, the analyst consensus on Atome Energy PLC is a Moderate Buy with an average price target of p135.00.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1937012632-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-atome-energy-plc-atom-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:18",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564039,
            "title": "Sylvania Platinum (SLP) Receives a Buy from Berenberg Bank",
            "description": "<p></p>\n<p>Hatch covers the Basic Materials sector, focusing on stocks such as Glencore, Wheaton Precious Metals, and Anglo American. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Hatch has an average return of <span style=\"color:green;font-weight:bold;\">16.0%</span> and a 54.44% success rate on recommended stocks. </p>\n<p>Sylvania Platinum has an analyst consensus of Moderate Buy, with a price target consensus of p109.00.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1496515682-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/sylvania-platinum-slp-receives-a-buy-from-berenberg-bank-blurbs-2",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:21",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564040,
            "title": "Aston Martin Lagonda Global Holdings plc (AML) Receives a Hold from J.P. Morgan",
            "description": "<p></p>\n<p>Kacker covers the Industrials sector, focusing on stocks such as Volvo AB, TRATON SE, and Daimler Truck Holding AG. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Kacker has an average return of <span style=\"color:red;font-weight:bold;\">-8.6%</span> and a 31.34% success rate on recommended stocks. </p>\n<p>The word on The Street in general, suggests a Hold analyst consensus rating for Aston Martin Lagonda Global Holdings plc with a p73.57 average price target, a 14.95% upside from current levels. In a report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a p64.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Consumer-Cylical-3-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/aston-martin-lagonda-global-holdings-plc-aml-receives-a-hold-from-j-p-morgan-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:24",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564041,
            "title": "J.P. Morgan Keeps Their Buy Rating on Prudential (PRU)",
            "description": "<p></p>\n<p>Hanif covers the Financial sector, focusing on stocks such as Prudential, ageas NV, and Assicurazioni Generali S.p.A.. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Hanif has an average return of <span style=\"color:green;font-weight:bold;\">8.0%</span> and a 64.79% success rate on recommended stocks. </p>\n<p>Prudential has an analyst consensus of Strong Buy, with a price target consensus of p1,225.91, implying a 14.95% upside from current levels. In a report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a p1,150.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2112464087-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-prudential-pru-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:28",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564042,
            "title": "J.P. Morgan Remains a Buy on Standard Chartered (SCBFF)",
            "description": "<p></p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Abouhossein is a 5-star analyst with an average return of <span style=\"color:green;font-weight:bold;\">23.6%</span> and a 70.22% success rate. Abouhossein covers the Financial sector, focusing on stocks such as HSBC Holdings, Standard Chartered, and Banco Comercial Portugues.</p>\n<p>In addition to J.P. Morgan, Standard Chartered also received a Buy from TR | OpenAI – 4o’s Lila Ledgerra  in a report issued on October 26. However, today, Goldman Sachs maintained a Hold rating on Standard Chartered (Other OTC: SCBFF).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_593873471-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-standard-chartered-scbff-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:33",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564043,
            "title": "Shore Capital Sticks to Their Buy Rating for GlobalData (DATA)",
            "description": "<p></p>\n<p></p>\n<p>In addition to Shore Capital, GlobalData also received a Buy from Deutsche Bank ‘s Steve Liechti in a report issued on October 20. However, on October 23, TR | OpenAI – 4o reiterated a Hold rating on GlobalData (LSE: DATA).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Industrials-7-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/shore-capital-sticks-to-their-buy-rating-for-globaldata-data-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:36",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564044,
            "title": "Shore Capital Reaffirms Their Hold Rating on Renishaw (RSW)",
            "description": "<p></p>\n<p></p>\n<p>Currently, the analyst consensus on Renishaw is a Hold with an average price target of p3,880.00, representing a 9.92% upside. In a report released on October 23, Jefferies also maintained a Hold rating on the stock with a p3,530.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2096992069-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/shore-capital-reaffirms-their-hold-rating-on-renishaw-rsw-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:38",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2564045,
            "title": "Shore Capital Reaffirms Their Hold Rating on Standard Chartered (SCBFF)",
            "description": "<p></p>\n<p></p>\n<p>Currently, the analyst consensus on Standard Chartered is a Moderate Buy with an average price target of $20.32, implying a 0.59% upside from current levels. In a report released today, Goldman Sachs also maintained a Hold rating on the stock with a p1,670.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1150180799-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/shore-capital-reaffirms-their-hold-rating-on-standard-chartered-scbff-blurbs",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2025-10-31 01:56:42",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        }
    ]
}